Shots:

• Ambrx to receive up front- development milestones and royalties on sales of ARX305 in China and retain rights to develop & commercialize ARX305 outside China. NovoCodex to get right to develop & commercialize ARX305 in China- will fund global activities to the end of P-I and is eligible to share ARX305 sales outside China
• Earlier- the companies collaborated to develop & commercialize ARX788- which is currently in P-I study for HER2 positive breast and gastric cancers
• ARX305 is an anti-CD70 ADC- expected to deliver direct killing to CD70-overexpressing tumor and improvement of the immune suppression in the tumor microenvironment with its anticipated onset of P-I study in H1’21  

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Xconomy